| Date | Title | Description |
| 17.09.2026 | Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR | — Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company —
TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinic... |
| 02.09.2026 | The Tech You’d Never Think Had Anything To Do With F1 | What do a racing bicycle, football technology, a prosthetic limb, a spacecraft, a factory and the car sitting in your driveway have in common? Actually, Formula 1 has something to do with all of them. Teams are constantly working on things ... |
| 28.08.2026 | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's | HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further adva... |
| 28.08.2026 | China’s InnoCare Pharma Turns a Profit in First Half on Surging Overseas Licensing Revenue | (Yicai) Aug. 28 -- Chinese drugmaker InnoCare Pharma swung into the black in the first half of the year, buoyed by rapid revenue growth from overseas licensing deals.
InnoCare had a net profit of CNY239.7 million (USD35.7 million) in the si... |
| 25.08.2026 | LifeMine Therapeutics Secures Landmark Funding, Reshaping Transplant Medicine | LifeMine Therapeutics secured $263 million. This landmark funding fuels a revolution in organ transplant medicine. The company's lead asset, LIFE-001, offers a next-generation approach. It targets rejection without severe toxicities. Tradit... |
| 19.08.2026 | LifeMine Therapeutics Secures $263M Series D & E |
WATERTOWN, MA, LifeMine Therapeutics, a clinical-stage biopharmaceutical company, announced $263 million in financing.
>> Click here for more funding data on LifeMine Therapeutics
>> To export LifeMine Therapeutics funding data... |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования
«Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 19.08.2026 | GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma | Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7
Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where a... |
| 18.08.2026 | Polymer Factory Sweden (publ) Interim Report Q2 | Polymer Factory Sweden (publ) Interim Report Q2
Tue, Aug 18, 2026 09:00 CET Report this content
Second quarter, April-June 2026
Polymer Factory Highlights Shimadzu Application News Featuring SpheriCal® Calibrants on MALDI-8020
The company P... |
| 11.08.2026 | Trump wants to split the MMR vaccine. Experts say that’s unlikely — and comes with consequences | President Donald Trump’s latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots.
But doctors and other experts say that effort has no scientific basis and is unlikely to get off ... |
| 11.08.2026 | ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Off... |
| 11.08.2026 | Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe | Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. (“SEVER”) for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Ph... |
| 10.08.2026 | Суд отказал «Биохимику» в принудительной лицензии на долутегравир | Суд отказал «Биохимику» в принудительной лицензии на долутегравир
Арбитражный суд Москвы отказал «Биохимику» (входит в ГК «Промомед») в принудительной лицензии на использование патента ViiV Healthcare Company и японской Shionogi, защищающег... |
| 07.08.2026 | LifeMine Therapeutics Raises $263M in Funding | LifeMine Therapeutics Inc., a Watertown, MA-based clinical-stage biopharmaceutical company leveraging digital genomics research technology, has raised $263M in funding.
The round included a $188M Series E financing led by Milky Way Investme... |
| 06.08.2026 | CoStar Data Shows Strong Prelet Activity Driving UK Lab Space Demand to a Record High | GSK’s landmark life sciences prelet drove UK laboratory space demand to a new record, according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets.
This press... |
| 06.08.2026 | Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas | A select group of private companies including Astrazeneca and Jaguar Land Rover will be able to endorse migrants to enter the UK on a skilled talent visa for the first time.
The list of over 100 companies, which also includes GSK, Arm and a... |
| 05.08.2026 | Pharma Giants Eye Colossal Merger: AstraZeneca and Bristol Myers Squibb in $400 Billion Talks | AstraZeneca and Bristol Myers Squibb reportedly discuss a $400 billion pharmaceutical megamerger. This potential tie-up would reshape the industry. The news sent AstraZeneca shares down, puzzling market analysts. Many question the strategic... |
| 02.08.2026 | AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports | UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times.
The megadeal would be one of the largest in history, creating a combined compa... |
| 30.07.2026 | GSK Backs Relation Therapeutics With $110M to Build Biological Data Factory | By James Whitaker
Published: Jul 30 2026, 10:00 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 29.07.2026 | Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Multip... |
| 28.07.2026 | Sweeping job cuts at GSK to fund £400m Cambridge campus | GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge, in a move it hopes will bolster its drugs pipeline anFd stave off a looming patent cliff-edge.
In his first major update as chief executive, Luk... |
| 20.07.2026 | CData Connect AI links healthcare organizations to protected health information | CData Connect AI links healthcare organizations to protected health information
CData Software announced that CData Connect AI now provides a governed AI data layer built for HIPAA-regulated environments—enabling healthcare providers, payer... |
| 14.07.2026 | Surgery-Free Rectal Cancer Treatment Edges Closer as Dostarlimab Clears Registrational Trial | By Frederick Rodriguez
Published: Jul 14 2026, 2:06 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 14.07.2026 | Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed By Utebzi Milestones And Royalties | Spero Therapeutics, a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates o... |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 07.07.2026 | BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong - Connecting Global Leaders in Biotechnology | Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.
HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong Kong International Biotechnology Conferenc... |
| 25.06.2026 | Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI | More than 450 executives from 100+ leading life sciences organizations gathered in Princeton, NJ to move agentic AI past the proof-of-concept stage
Founder and CEO Jaswinder "Jassi" Chadha challenged the industry with a counterint... |
| 16.06.2026 | Biotech IPO revival faces competition from cash-rich big pharma buyers | Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan’s top EMEA healthcare investment bankers told CNBC.
Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simu... |
| 10.06.2026 | Podcast: Palantir to sue Sadiq Khan, GSK’s $10bn mega-deal, and could the World Cup rescue pubs? | In today’s episode of City AM’s Business As Usual podcast, we get stuck in the top stories of the day – from a major pharma M&A deal to a US software giant poised to take legal action against the Mayor of London.
City Editor Simon Hunt ... |
| 09.06.2026 | GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn | Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent.
The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was t... |
| 09.06.2026 | More swings for AI stocks drag Wall Street back on the roller coaster | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — Another sudden reversal for high-flying artificial-intelligence stocks sent Wall Street reeling on Tuesday.
The S&P 500 fell 0.3% after careenin... |
| 09.06.2026 | GSK покупает американскую Nuvalent за $10,6 млрд для усиления онкологического портфеля | Британская фармкомпания GSK договорилась о покупке американского разработчика онкологических препаратов Nuvalent за $10,6 млрд. Это крупнейшая сделка компании более чем за десятилетие и часть стратегии нового CEO Лукаса Мьельса по усилению ... |
| 09.06.2026 | GSK in talks to buy cancer biotech Nuvalent for more than $9 billion | - |
| 09.06.2026 | GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares | GSK has said agentic AI is already affecting every asset in its pipeline, as pharmaceutical firms race to use the technology to cut the cost and risk of developing new medicines.
Speaking at London Tech Week in Tuesday, Eyal Itskovitz, GSK’... |
| 02.06.2026 | Microsoft Discovery Reaches GA at Build 2026 Bringing Agentic AI to Scientific Research | News Microsoft Discovery Reaches GA at Build 2026 Bringing Agentic AI to Scientific Research By Chris PaoliJune 02, 2026
Key Takeaways
Microsoft Discovery reaches general availability, bringing agentic AI to scientific research and developm... |
| 28.05.2026 | Experimental hepatitis B drug may offer ‘functional cure’ for some patients | Getting your Trinity Audio player ready...
By LAURAN NEERGAARD, AP Medical Writer
WASHINGTON (AP) — A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s ... |
| 27.05.2026 | Lilly to acquire LimmaTech Biologics for up to USD 780 million |
LimmaTech is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. The company'... |
| 21.05.2026 | WCIFIT Opens in Chongqing with 1,400 Global Firms, Showcasing Robots, Flying Cars, and Local Cuisine | CHONGQING, China, May 21, 2026 /PRNewswire/ -- A news report from iChongqing - The 8th Western China International Fair for Investment and Trade (WCIFIT) opened in Chongqing on May 21, bringing together nearly 1,400 companies from 50 countr... |
| 18.05.2026 | Gradiant Closes Series E Funding, at $2 Billion Valuation | Gradiant, a Boston, MA-based provider of advanced water and wastewater treatment solutions, raised an undisclosed amount in Series E funding, at $2M Billion valuation.
The round was led by Safar Partners and Hostplus Superannuation Fund, wi... |
| 12.05.2026 | SBP to Speed Up Commercialization of GSK's New Hepatitis B Drug in China | (Yicai) May 12 -- Sino Biopharmaceutical Group has entered into a strategic partnership with UK pharmaceutical giant GlaxoSmithKline to accelerate the commercialization of bepirovirsen, a new drug for the treatment of chronic hepatitis B, i... |
| 05.05.2026 | Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent | Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, a... |
| 22.04.2026 | Shingles: More than a rash, a painful condition not to ignore | Listen
6 min
New: You can now listen to articles.
This audio is generated by an AI tool.
When Mediacorp artiste and member of the OG Gang member Chen Shu Cheng first noticed small, red, itchy spots on the right side of his waist, he initial... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 31.03.2026 | Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare ex... | Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of str... |
| 31.03.2026 | Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland | Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters
Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support
Plans further... |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio.
It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 26.03.2026 | Hengrui Pharma Announces Strong 2025 Annual Results | SHANGHAI, March 26, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% y... |
| 24.03.2026 | DualityBio (9606.HK) Announces 2025 Annual Results | HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biop... |
| 24.03.2026 | WuXi Biologics Reports Record 2025 Annual Results | Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)
EBITDA rose 38.1%... |
| 24.03.2026 | Gilead покупает Ouro Medicines более чем за $2 млрд и усиливает ставку на иммунологию | По условиям сделки Gilead выплатит инвесторам Ouro $1,68 млрд авансом наличными, а также еще до $500 млн в случае достижения определенных этапов разработки препарата. Ключевым активом в этой покупке является экспериментальный препарат OM336... |
| 23.03.2026 | Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss | Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial.
Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited “strong efficacy” for its ... |
| 18.03.2026 | Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science Startups | Breakout Ventures has announced the close of its $114 million Fund III, marking a new phase of investment focused on science-driven startups at the intersection of biology, chemistry, and artificial intelligence.
The San Francisco-based ven... |
| 12.03.2026 | ELRIG Announces Prof Hazel Screen and Dr Dave Powell as Keynote Speakers for Advances in Cell-based Screening 2026 | • Free-to-attend conference takes place at AstraZeneca in Gothenburg, Sweden from 6–7 May • Programme to focus on advancement of animal-replacement technologies and transition towards human-first, AI-driven drug discovery
Cambridge, UK, 12 ... |
| 10.03.2026 | Biocaptiva Secures £1.58M, Unveils Pioneering Liquid Biopsy Tech in US | Biocaptiva, an Edinburgh biotech firm, secured £1.58M in new funding. They launched their innovative msX magnetic bead technology in the US. This platform extracts cell-free DNA directly from whole blood. It eliminates traditional liquid bi... |
| 10.03.2026 | FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment | The Food and Drug Administration approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children.
The move comes months after the Trump administration touted le... |
| 10.03.2026 | Breakout Ventures: $114 Million Fund III Launched To Back Science-Driven Startups Using AI | Breakout Ventures announced the close of its $114 million Fund III, expanding the venture firm’s efforts to back early-stage companies working at the intersection of science, technology, and artificial intelligence. The San Francisco-based ... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 10.03.2026 | FDA finds little evidence that a drug touted by Trump can help people with autism | Getting your Trinity Audio player ready...
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — The Food and Drug Administration on Tuesday approved a generic medication for a rare brain disorder, while walking back statements by Presiden... |
| 09.03.2026 | University of Edinburgh biotech spin-out BIOCAPTIVA raises £1.58M | University of Edinburgh spin-out BIOCAPTIVA has raised £1.58 million in a new funding round and launched its first product in the US.
BIOCAPTIVA’s novel magnetic bead technology is designed to solve one of liquid biopsy’s biggest bottleneck... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 26.02.2026 | GSK calls for more conversations on shingles prevention in adults | - |
| 25.02.2026 | ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults livin... |
| 25.02.2026 | ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase str... |
| 25.02.2026 | Британская GSK покупает канадскую биотехкомпанию 35Pharma за $950 млн | Компания GSK сообщила в среду, что согласилась выплатить $950 млн наличными за канадскую биотехнологическую компанию 35Pharma, что стало второй крупной сделкой нового генерального директора Люка Мийелса, направленной на ускорение разработки... |
| 24.02.2026 | China's Frontier Biotech Pops After Granting GSK Rights to Two siRNA Drugs in USD1 Billion Deal | (Yicai) Feb. 24 -- Shares of Frontier Biotechnologies surged after the Chinese drugmaker granted UK pharmaceutical giant GSK the exclusive global rights to two small nucleic acid therapies it is developing in a deal worth more than USD1 bil... |
| 23.02.2026 | Moderna mRNA Flu Vaccine Gains FDA Review Amid Regulatory Shift | FDA will review Moderna's mRNA flu vaccine. This reverses an initial refusal. Moderna proposed a new regulatory path. It seeks full approval for adults 50-64. Accelerated approval is requested for ages 65 and up. A post-market study will fo... |
| 19.02.2026 | Global Counsel to be placed into administration | Global Counsel’s 130 staff have been informed that the lobbying company founded by Peter Mandelson will be placed into administration as soon as tomorrow.
City AM understands that despite a number of clients deciding to stay with the firm, ... |
| 19.02.2026 | In reversal, US agrees to review new Moderna flu shot | NEW YORK: Vaccine manufacturer Moderna said Wednesday (Feb 18) the US Food and Drug Administration walked back its previous position and agreed to review the company's new mRNA-based flu shot.
Last week the US firm said the federal vaccine ... |
| 19.02.2026 | Altesa BioSciences: $75 Million Series B Raised For Advancing Vapendavir For Chronic Lung Diseases | Altesa BioSciences, a clinical-stage pharmaceutical company focused on improving outcomes for people with chronic lung diseases, has closed an oversubscribed $75 million Series B financing round to advance development of vapendavir, a first... |
| 14.02.2026 | Mars Appoints Manish Syag as Managing Director for its Pet Nutrition Business in India | Delhi, India
Today, Mars, Incorporated announced the appointment of Manish Syag as Managing Director of its Pet Nutrition division in India. Manish will lead the business, home to some of the country’s most trusted and pioneering pet food b... |
| 11.02.2026 | CNBC’s UK Exchange newsletter: Compass shifts its trading to dollars — and it might not be the last | A recent change to the rules governing how companies may be admitted to indices, like the FTSE 100, run by FTSE Russell means those whose shares change hands in dollars and euros may now enter these indices.
It has prompted a couple of Foot... |
| 11.02.2026 | Global Counsel loses more clients as Epstein scandal deepens | The crisis engulfing the lobbying firm founded by Peter Mandelson, Global Counsel, deepened on Tuesday, after three more of its blue-chip clients parted ways with the advisory over its links to co-founder Mandelson and the convicted sex tra... |
| 10.02.2026 | Lobbying chief urges firms not to work with unregistered agencies | The boss of the lobbying sector’s industry body has urged public affairs chiefs to stop working with agencies that have not signed up to its code of conduct, after several blue-chip companies were forced to sever ties with Peter Mandelson’s... |
| 10.02.2026 | Mandelson’s Global Counsel has been rocked by its links to Epstein. Will it survive? | Global Counsel – the lobbying shop co-founded by Peter Mandelson – was once a swashbuckling force in London’s world-leading public affairs sector. But after the extent of its links to Jeffrey Epstein were revealed by the US Department of Ju... |
| 06.02.2026 | Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia | SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received ... |
| 06.02.2026 | PDA Introduces the 2026 Board of Directors and Officers | PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences.
BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 05.02.2026 | ‘Look out for rich individuals’: The deep ties between Mandelson lobbying firm and Epstein | As one of London’s many eminent lobbying and advisory outfits, Peter Mandelson’s Global Counsel is well versed in what it takes to manage a reputation.
Set up by the former deputy Prime Minister and Labour spin doctor Benjamin Wegg-Prosser ... |
| 04.02.2026 | Market Volatility Rocks US Stocks Amid Major Corporate Shifts and Mega-Mergers | US markets plunged. Tech and software stocks saw steep declines. Artificial intelligence concerns fueled investor anxiety. UBS reported robust earnings, beating forecasts. Its shares rose. Conversely, Novo Nordisk projected slowing growth. ... |
| 04.02.2026 | Santander falls nearly 4% amid plan to buy U.S. bank Webster for $12.2 billion | LONDON — European stocks opened in flat-to-higher territory on Wednesday amid a slew of corporate earnings reports in the region.
The pan-European Stoxx 600 was trading just above the flatline shortly after the market open.
The U.K.’s FTSE ... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 01.02.2026 | AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation | AstraZeneca has announced it’s investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs.
The developments come at a critical time for the pharma industry as companies are increasingly lo... |
| 31.01.2026 | Britain's China Strategy: Billions Invested, Relations Realigned | UK Prime Minister Keir Starmer concluded a pivotal visit to China. He pursued stronger economic ties. AstraZeneca announced a $15 billion investment in Chinese pharmaceuticals. A visa-free travel deal was secured for UK citizens visiting Ch... |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 29.01.2026 | New Board of Directors at Everdrone ahead of accelerated expansion | New Board of Directors at Everdrone ahead of accelerated expansion
Thu, Jan 29, 2026 09:53 CET Report this content
Everdrone AB announces the appointment of a new Board of Directors, following a decision at an Extraordinary General Meeting ... |
| 29.01.2026 | Британская AstraZeneca планирует инвестировать $15 млрд в Китай до 2030 года | Компания с штаб-квартирой в Кембридже (Англия) заявила, что инвестиции помогут «создавать лекарства нового поколения».
«Сегодняшняя знаковая инвестиция в $15 млрд открывает захватывающую новую главу для AstraZeneca в Китае, который стал клю... |
| 29.01.2026 | Starmer: Businesses ‘cry out’ for more trade with China | Keir Starmer has said businesses are “crying out for ways” to export to Chinese markets as he struck a new deal for British travellers.
After meeting President Xi Jinping in China, Starmer defended his government’s ambitions to boost relati... |
| 29.01.2026 | ‘No comment’: City firms on Starmer China trip keep schtum | When Sir Keir Starmer boarded a British Airways flight to Beijing earlier this week, he brought with him a coterie of leaders from British industry to help fly the flag.
More than 50 delegates were invited on the PM’s trip, many from top Ci... |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 28.01.2026 | Airbus, AstraZeneca and HSBC executives join UK’s Starmer on high-stakes China trip | Starmer brings nearly 60 business and cultural groups on first U.K. leader visit to China in eight years.
Talks with Xi and Li focus on trade, investment and national security.
Visit follows a surge of foreign leaders engaging Beijing amid ... |
| 28.01.2026 | CNBC Daily Open: Starmer’s high stakes visit to China takes center stage | British businesses to join Starmer’s China visit.
S&P 500 marks record close.
A partial U.S. government shutdown.
Amazon accidentally sends email confirming cloud unit layoffs.
Two ways to play the energy sector.
All eyes are on U.K. Pr... |
| 28.01.2026 | Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer | Sigrid Therapeutics appoints Claus Kjaersgaard as Chief Executive Officer
Wed, Jan 28, 2026 08:30 CET Report this content
Stockholm, 28 January 2026 — Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovat... |
| 28.01.2026 | Lib Dems: Starmer has gone ‘cap in hand’ to China despite spy threats | Keir Starmer has been accused of going “cap in hand” to China, piling further criticism on the government’s trade ambitions with a country that has backed hacking operations against the UK.
Liberal Democrats deputy leader Daisy Cooper deman... |
| 27.01.2026 | Starmer under fire over China trip amid phone-hacking revelations | Keir Starmer is under fire over his a trade-focused trip to China this week as further reports of espionage emerged.
Chinese officials are believed to have hacked the phones of key government officials, according to The Telegraph.
Hackers t... |
| 26.01.2026 | Andy Haldane: Labour has ‘no nose for business’ | The Labour government lacks anyone with a “nose for business”, Andy Haldane, the former chief economist of the Bank of England, has said in his latest critique against ministers’ quest for growth.
Haldane, whose criticism of Budget leaks la... |
| 25.01.2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| 25.01.2026 | London's King's Cross: A Global Powerhouse Emerges | London's King's Cross has transformed into a global innovation and retail powerhouse. Once a neglected area, it now thrives as a leading tech and life sciences hub, attracting major investment and creating high-value jobs. Retail sales show... |
| 23.01.2026 | NVIDIA и Eli Lilly вложат $1 млрд в ИИ-лабораторию лекарств | NVIDIA и фармацевтический гигант Eli Lilly объявили о создании совместной ИИ-лаборатории с инвестициями до $1 млрд на пять лет. Лаборатория расположится в Сан-Франциско и объединит биологов и химиков Lilly с инженерами NVIDIA для круглосуто... |
| 22.01.2026 | GSK Awards $2 Million In COiMMUNITY Grants To Help Close Vaccination Gaps And Pledges $3 Million for 2026 | GSK announced it has awarded $2 million in grants to 16 state, regional, and national nonprofit organizations through its COiMMUNITY Initiative, as the biopharma company seeks to support local efforts to improve vaccine education, communica... |
